Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion
Franklin C. Lowe(St. Luke's-Roosevelt Hospital Center), Herman Stoevelaar(Barnes-Jewish Hospital), Michael P. O’Leary(University of California, Irvine), Bianca Meesen(Exmar (Belgium)), Emmanuel Chartier‐Kastler(Sorbonne Université), Gabriele Conti(University of Bologna), John Trachtenberg(Ministry of Health), Andrea Tubaro(Sapienza University of Rome), K. Dreikorn, Louis Smets, F. Desgrandchamps, J.E. Batista(Puigvert Foundation), Marcelo Vaz Perez(Universidade Federal de São Paulo), R. Berges(Ruhr University Bochum), Mark Speakman(Taunton & Somerset NHS Foundation Trust)
Cited by 29
Related Papers
Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
|The Lancet|1995|290
Urology practice during the COVID-19 pandemic
|Minerva Urologica e Nefrologica|2020|256
Adenocarcinoma of the Prostate
|Clinical practice in urology|1987|207
Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?
|European Urology|2020|207
International Continence Society best practice statement for use of sacral neuromodulation
|Neurourology and Urodynamics|2018|173